Mechanistically, talazoparib inhibits tumour cell growth through promoting lncRNA PLK4 up‐regulation specifically, followed by YAP inactivation, ultimately leading to cellular senescence of hepatoma cells. The gene discussed is PLK4; the disease is hepatocellular carcinoma.